The Membrane Complement Regulatory Protein CD59 and Its Association with Rheumatoid Arthritis and Systemic Lupus Erythematosus

Total Page:16

File Type:pdf, Size:1020Kb

The Membrane Complement Regulatory Protein CD59 and Its Association with Rheumatoid Arthritis and Systemic Lupus Erythematosus Current Medicine Research and Practice 9 (2019) 182e188 Contents lists available at ScienceDirect Current Medicine Research and Practice journal homepage: www.elsevier.com/locate/cmrp Review Article The membrane complement regulatory protein CD59 and its association with rheumatoid arthritis and systemic lupus erythematosus * Nibhriti Das a, Devyani Anand a, Bintili Biswas b, Deepa Kumari c, Monika Gandhi c, a Department of Biochemistry, All India Institute of Medical Sciences, New Delhi 110029, India b Department of Zoology, Ramjas College, University of Delhi, India c University School of Biotechnology, Guru Gobind Singh Indraprastha University, India article info abstract Article history: The complement cascade consisting of about 50 soluble and cell surface proteins is activated in auto- Received 8 May 2019 immune inflammatory disorders. This contributes to the pathological manifestations in these diseases. In Accepted 30 July 2019 normal health, the soluble and membrane complement regulatory proteins protect the host against Available online 5 August 2019 complement-mediated self-tissue injury by controlling the extent of complement activation within the desired limits for the host's benefit. CD59 is a membrane complement regulatory protein that inhibits the Keywords: formation of the terminal complement complex or membrane attack complex (C5b6789n) which is CD59 generated on complement activation by any of the three pathways, namely, the classical, alternative, and RA SLE the mannose-binding lectin pathway. Animal experiments and human studies have suggested impor- Pathophysiology tance of membrane complement proteins including CD59 in the pathophysiology of rheumatoid arthritis Disease marker (RA) and systemic lupus erythematosus (SLE). Here is a brief review on CD59 and its distribution, structure, functions, and association with RA and SLE starting with a brief introduction on the com- plement system, its activation, the biological functions, and relations of membrane complement regu- latory proteins, especially CD59, with RA and SLE. © 2019 Sir Ganga Ram Hospital. Published by Elsevier, a division of RELX India, Pvt. Ltd. All rights reserved. 1. Introduction (Fig. 1 a). To name a few, immune complexes, altered self-mole- cules, and microbial mannose surfaces trigger the classical, alter- The complement system represents about fifty cell surface and native, and lectin pathways, respectively. The activation takes place soluble proteins consisting of zymogens, receptors, and regulators. in a step-wise cascade manner flowing down from the 1st com- The zymogens get activated by three different pathways, namely, plement component C1 (qrs) to the terminal complement compo- the classical pathway, the alternative pathway, and the mannose- nent C9 via the activation of C2, C4, C3 and C5 ending in a binding lectin pathway triggered by different molecular patterns nonenzymatic assembly of C6eC9 with active fragment from C5. On activation, the conversion of inactive zymogens to biologically active peptides occurs by the cleavage of the parent protein, the primary fragments named as ‘a’ and ‘b’ such as C3a, C3b, C4a, C4b, Abbreviations: MAC, Membrane attack complex; CRPs, Complement regulatory proteins; TCC, Terminal complement complex; DAF, decay-accelerating factor; MCP, C5a, and C5b. The classical pathway commences with the activation Membrane cofactor protein; fH, Factor H; SLE, Systemic lupus erythematosus; RA, of C1, alternative pathway with the activation of C3, and the lectin Rheumatoid arthritis; OA, Osteoarthritis; HRF-2, Homologous Restriction factor-2; pathway with the activation of C2 and C4. GPI, glycosylphosphatidylinositol; LPS, Lipopolysaccharide; RTX, Rituximab; AA, Each of the active peptides has effecter functions expedited by Aplastic anemia; PNH, Paroxysmal nocturnal hemoglobinuria; AIMF, Autoimmune fi myelofibrosis; PBMC, Peripheral Blood Mononuclear Cells. their interactions with the speci c cell surface receptors. C3a and * Corresponding author. University School of Biotechnology, Guru Gobind Singh C5a are endowed with strong chemotactic and anaphylactic prop- Indraprastha University, Sector16c, Dwarka, New Delhi 110019, India. erties, whereas C3b and C4b are opsonins. In addition, C5b gets E-mail addresses: [email protected] (N. Das), [email protected] assembled with C6-9 to form a terminal complement complex C5b- (D. Anand), [email protected], [email protected] (B. Biswas), 6-7-8-9(n) also known as the membrane attack complex (MAC). [email protected] (D. Kumari), [email protected] (M. Gandhi). https://doi.org/10.1016/j.cmrp.2019.07.013 2352-0817/© 2019 Sir Ganga Ram Hospital. Published by Elsevier, a division of RELX India, Pvt. Ltd. All rights reserved. N. Das et al. / Current Medicine Research and Practice 9 (2019) 182e188 183 Fig. 1. (a) The complement cascade and activation pathways.1 (b) Inhibition of MAC assembly by CD59.20 MAC, membrane attack complex. MAC forms a pore in the microbial membranes on which it got Here is a brief review on the membrane complement regulatory assembled after the cascade activation. protein CD59 and its association with the systemic autoimmune The system is the first line of defense against invading disorders RA and SLE. pathogens, but activation, if goes unabated, leads to severe in- flammatory reactions and self-tissue injury because of the 2. CD59 (protectin/membrane inhibitor of reactive lysis/HRF- bystander or targeted effects of the MAC and the inflammatory 20/MACIF) peptides. In normal health, the self-injury by complement activation re- CD59 is a membrane-bound regulator of the C cascade.2 In mains insignificant because of the very stringent control effected by humans, CD59 is broadly expressed in the cell surface of different soluble and cell surface membrane complement regulatory proteins. tissues except erythrocytes. A soluble truncated form of CD59 is In autoimmune inflammatory disorders, exaggerated activation present in plasma and other body fluids.3 of the complement cascade had been evidenced. Studies are in progress to determine the role of complement 2.1. Structure of CD59 regulatory proteins in these diseases and also to explore their po- tential as disease markers and therapeutic targets. CD59 is an 18- to 20-kDa molecular-weight glyco- A set of complement regulatory proteins such as complement sylphosphatidylinositol (GPI)eanchored glycoprotein. The protein receptor 1 (CR1 or CD35), factor H (fH), decay-accelerating factor consists of 103 amino acid residues, with the first 25 amino acids (DAF or CD55), membrane cofactor protein (MCP or CD46), and constituting the signal sequence and the final 26 amino acids protectin (CD59) have been shown to be associated with the forming the GPI anchor. It has a single N-glycosylation site (N18 in pathogenesis of rheumatoid arthritis (RA) and systemic lupus ery- human CD59) and several potential O-glycosylation sites. This 1 thematosus (SLE). structure is characterized as a single cysteine-rich domain, having a 184 N. Das et al. / Current Medicine Research and Practice 9 (2019) 182e188 þ hydrophobic core with three loops and a small fourth loop, which is upregulation of CD59 on activated CD4 T cells which served to helical.4 The helical loop is made of two antiparallel beta sheets, downmodulate their activity in response to polyclonal and Ag- and the other three loops are three antiparallel beta sheets, which specific stimulation.21 Thus, CD59 is suggested to have a regulato- form the core. Connecting each of these loops are five disulphide- ry effect on T cells. In addition, CD59 is endowed with several bonded cysteine pairs. pleotropic functions. The soluble CD59 derived from urine does not possess an intact GPI anchor, is unable to insert into cells, and is consequently a poor 3.3. Functions of CD59 MAC inhibitor. In contrast, soluble CD59 from amniotic fluid, seminal plasma, and cerebrospinal fluid retains its GPI anchor, can Alternative roles of CD59 interacting with different proposed incorporate into cell membranes, and is an efficient MAC inhibitor.5 ligands are depicted in Fig. 2.22 Human CD59 is closely related to mouse Ly6 antigen.6 The hu- man gene gives rise to more than 4 different mRNA molecules, 1. The complement regulator CD59 has a major protective role which are generated by alternative polyadenylation.7 against autolysis of cells and tissues by the complement system. The gene for CD59 is localized on region p14-p13 of the short 2. CD59 localized in lipid raft as glycosylphosphatidylinositol arm of chromosome 11.8 The CD59 gene consists of 4 exons. The (GPI)-anchored protein helps in maintaining the stability of lipid first exon is untranslated, the second encodes the hydrophobic raft in various cell types. leader sequence of the protein, the third exon encodes the N-ter- 3. CD59 as another ligand for CD2 induces signal transduction minal portion of the mature protein, and the fourth exon encodes pathway in T-cell activation. the remainder of the mature protein including the GPI anchor 4. It is also involved in endocytosis of CD59-C9 complex by attachment in the plasma membrane. signaling the cells. 5. CD59 mediates the attenuation of angiogenesis by preventing 2.2. Expression of CD59 the lysis of newly grown blood vessels by complement cascade. 6. CD59 through complement-independent role transduces the CD59 is widely expressed in human cells and tissues. It is pre- lipopolysaccharide (LPS) signal into the nucleus via Nuclear sent on all circulating cells9, endothelial cells10,
Recommended publications
  • Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse
    Welcome to More Choice CD Marker Handbook For more information, please visit: Human bdbiosciences.com/eu/go/humancdmarkers Mouse bdbiosciences.com/eu/go/mousecdmarkers Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse CD3 CD3 CD (cluster of differentiation) molecules are cell surface markers T Cell CD4 CD4 useful for the identification and characterization of leukocytes. The CD CD8 CD8 nomenclature was developed and is maintained through the HLDA (Human Leukocyte Differentiation Antigens) workshop started in 1982. CD45R/B220 CD19 CD19 The goal is to provide standardization of monoclonal antibodies to B Cell CD20 CD22 (B cell activation marker) human antigens across laboratories. To characterize or “workshop” the antibodies, multiple laboratories carry out blind analyses of antibodies. These results independently validate antibody specificity. CD11c CD11c Dendritic Cell CD123 CD123 While the CD nomenclature has been developed for use with human antigens, it is applied to corresponding mouse antigens as well as antigens from other species. However, the mouse and other species NK Cell CD56 CD335 (NKp46) antibodies are not tested by HLDA. Human CD markers were reviewed by the HLDA. New CD markers Stem Cell/ CD34 CD34 were established at the HLDA9 meeting held in Barcelona in 2010. For Precursor hematopoetic stem cell only hematopoetic stem cell only additional information and CD markers please visit www.hcdm.org. Macrophage/ CD14 CD11b/ Mac-1 Monocyte CD33 Ly-71 (F4/80) CD66b Granulocyte CD66b Gr-1/Ly6G Ly6C CD41 CD41 CD61 (Integrin b3) CD61 Platelet CD9 CD62 CD62P (activated platelets) CD235a CD235a Erythrocyte Ter-119 CD146 MECA-32 CD106 CD146 Endothelial Cell CD31 CD62E (activated endothelial cells) Epithelial Cell CD236 CD326 (EPCAM1) For Research Use Only.
    [Show full text]
  • Role of C5ar1 and C5L2 Receptors in Ischemia-Reperfusion Injury
    Journal of Clinical Medicine Article Role of C5aR1 and C5L2 Receptors in Ischemia-Reperfusion Injury Carlos Arias-Cabrales 1,* , Eva Rodriguez-Garcia 1, Javier Gimeno 2, David Benito 3, María José Pérez-Sáez 1, Dolores Redondo-Pachón 1, Anna Buxeda 1, Carla Burballa 1, Marta Crespo 1, Marta Riera 3,* and Julio Pascual 1,* 1 Department of Nephrology, Parc de Salut Mar, 08003 Barcelona, Spain; [email protected] (E.R.-G.); [email protected] (M.J.P.-S.); [email protected] (D.R.-P.); [email protected] (A.B.); [email protected] (C.B.); [email protected] (M.C.) 2 Department of Pathology, Parc de Salut Mar, 08003 Barcelona, Spain; [email protected] 3 Kidney Research Group, Hospital del Mar Medical Research Institute, IMIM, 08003 Barcelona, Spain; [email protected] * Correspondence: [email protected] (C.A.-C.); [email protected] (M.R.); [email protected] (J.P.) Abstract: The role of C5a receptors (C5aR1 and C5L2) in renal ischemia-reperfusion injury (IRI) is uncertain. We generated an in vitro model of hypoxia/reoxygenation with human proximal tubule epithelial cells to mimic some IRI events. C5aR1, membrane attack complex (MAC) and factor H (FH) deposits were evaluated with immunofluorescence. Quantitative polymerase chain reaction evaluated the expression of C5aR1, C5L2 genes as well as genes related to tubular injury, inflammation, and profibrotic pathways. Additionally, C5aR1 and C5L2 deposits were evaluated in kidney graft biopsies (KB) from transplant patients with delayed graft function (DGF, n = 12) and compared with Citation: Arias-Cabrales, C.; a control group (n = 8). We observed higher immunofluorescence expression of C5aR1, MAC and FH Rodriguez-Garcia, E.; Gimeno, J.; as higher expression of genes related to tubular injury, inflammatory and profibrotic pathways and Benito, D.; Pérez-Sáez, M.J.; of C5aR1 in the hypoxic cells; whereas, C5L2 gene expression was unaffected by the hypoxic stimulus.
    [Show full text]
  • More Than a Pore: Nonlytic Antimicrobial Functions of Downloaded from Complement and Bacterial Strategies for Evasion
    REVIEW More than a Pore: Nonlytic Antimicrobial Functions of Downloaded from Complement and Bacterial Strategies for Evasion Elisabet Bjanes,a Victor Nizeta,b aDivision of Host-Microbe Systems and Therapeutics, Department of Pediatrics, UC San Diego, La Jolla, California, USA bSkaggs School of Pharmacy and Pharmaceutical Sciences, UC San Diego, La Jolla, California, USA http://mmbr.asm.org/ SUMMARY ........................................................................1 INTRODUCTION ...................................................................2 BY THE BOOK: CANONICAL COMPLEMENT CASCADES ...............................2 Off to the Races—Pathway Activation . 2 More and More—Amplification . 3 End of the Line—Termination . 3 Pump the Brakes—Inhibition . 5 Surviving MAC Attack—Evasion of Complement Lysis by Gram-Negative Bacteria . 6 NONLYTIC COMPLEMENT FUNCTIONS AND BACTERIAL EVASION MECHANISMS ......8 Special Considerations in Gram-Positive Bacteria . 8 on January 27, 2021 at UNIV OF CALIF SAN DIEGO Preparing the Meal—Complement Aids Opsonization and Phagocytosis . 8 Food for Thought—Complement Traffics to Autophagy . 10 Fueling the Fire—Complement Modulates Inflammatory Responses . 11 Casting a Wider NET—Complement and Neutrophil Synergy . 12 Inside Scoop—Novel Roles of Intracellular Complement . 13 Tying the Clot—Complement and Coagulation Cross Talk . 15 Bridging the Gap—Complement Instructs Adaptive Immunity . 17 REFRAMING SCIENTIFIC PARADIGMS AND THERAPEUTIC APPROACHES TO ENCOMPASS COMPLEMENT ..................................................18
    [Show full text]
  • An Anticomplement Agent That Homes to the Damaged Brain and Promotes Recovery After Traumatic Brain Injury in Mice
    An anticomplement agent that homes to the damaged brain and promotes recovery after traumatic brain injury in mice Marieta M. Rusevaa,1,2, Valeria Ramagliab,1, B. Paul Morgana, and Claire L. Harrisa,3 aInstitute of Infection and Immunity, School of Medicine, Cardiff University, Cardiff CF14 4XN, United Kingdom; and bDepartment of Genome Analysis, Academic Medical Center, Amsterdam 1105 AZ, The Netherlands Edited by Douglas T. Fearon, Cornell University, Cambridge, United Kingdom, and approved September 29, 2015 (received for review July 15, 2015) Activation of complement is a key determinant of neuropathology to rapidly and specifically inhibit MAC at sites of complement and disability after traumatic brain injury (TBI), and inhibition is activation, and test its therapeutic potential in experimental TBI. neuroprotective. However, systemic complement is essential to The construct, termed CD59-2a-CRIg, comprises CD59a linked fight infections, a critical complication of TBI. We describe a to CRIg via the murine IgG2a hinge. CD59a prevents assembly targeted complement inhibitor, comprising complement receptor of MAC in cell membranes (16), whereas CRIg binds C3b/iC3b of the Ig superfamily (CRIg) fused with complement regulator CD59a, deposited at sites of complement activation (17). The IgG2a designed to inhibit membrane attack complex (MAC) assembly at hinge promotes dimerization to increase ligand avidity. CD59- sites of C3b/iC3b deposition. CRIg and CD59a were linked via the 2a-CRIg protected in the TBI model, demonstrating that site- IgG2a hinge, yielding CD59-2a-CRIg dimer with increased iC3b/C3b targeted anti-MAC therapeutics may be effective in prevention binding avidity and MAC inhibitory activity. CD59-2a-CRIg inhibited of secondary neuropathology and improve neurologic recovery MAC formation and prevented complement-mediated lysis in vitro.
    [Show full text]
  • Quantitation of the Number of Molecules of Glycophorins C and D on Normal Red Blood Cells Using Radioiodinatedfab Fragments of Monoclonal Antibodies
    Quantitation of the Number of Molecules of Glycophorins C and D on Normal Red Blood Cells Using RadioiodinatedFab Fragments of Monoclonal Antibodies By Jon Smythe, Brigitte Gardner, andDavid J. Anstee Two rat monoclonal antibodies (BRAC 1 and BRAC 1 1 ) cytes. Fabfragments of BRAC 1 1 and ERIC 10 gave values have been produced. BRAC 1 recognizes an epitope com- of 143,000 molecules GPC per red blood cell (RBC). Fab mon to the human erythrocyte membrane glycoproteins fragments of BRAC1 gave 225,000 molecules of GPC and glycophorin C (GPC) and glycophorin D (GPD). BRAC 11 GPD per RBC. These results indicate that GPC and GPD is specific for GPC. Fabfragments of these antibodies and together are sufficiently abundantto provide membrane at- BRlC 10, a murine monoclonal anti-GPC,were radioiodin- tachment sites for all ofthe protein 4.1 in normal RBCs. ated and used in quantitative binding assays to measure 0 1994 by The American Societyof Hematology. the number of GPC and GPD molecules on normal erythro- HE SHAPE AND deformability of the mature human (200,000)" and those reported for GPC (50,000).7 This nu- Downloaded from http://ashpublications.org/blood/article-pdf/83/6/1668/612763/1668.pdf by guest on 24 September 2021 T erythrocyte is controlled by a flexible two-dimensional merical differencehas led to the suggestion that a significant lattice of proteins, which together comprise the membrane proportion of protein 4.1 in normal erythrocyte membranes skeleton.' The major components of the skeleton are spec- must be bound to sites other than GPC and GPD.3 The trin, actin, ankyrin, and protein 4.1.
    [Show full text]
  • CD Markers Are Routinely Used for the Immunophenotyping of Cells
    ptglab.com 1 CD MARKER ANTIBODIES www.ptglab.com Introduction The cluster of differentiation (abbreviated as CD) is a protocol used for the identification and investigation of cell surface molecules. So-called CD markers are routinely used for the immunophenotyping of cells. Despite this use, they are not limited to roles in the immune system and perform a variety of roles in cell differentiation, adhesion, migration, blood clotting, gamete fertilization, amino acid transport and apoptosis, among many others. As such, Proteintech’s mini catalog featuring its antibodies targeting CD markers is applicable to a wide range of research disciplines. PRODUCT FOCUS PECAM1 Platelet endothelial cell adhesion of blood vessels – making up a large portion molecule-1 (PECAM1), also known as cluster of its intracellular junctions. PECAM-1 is also CD Number of differentiation 31 (CD31), is a member of present on the surface of hematopoietic the immunoglobulin gene superfamily of cell cells and immune cells including platelets, CD31 adhesion molecules. It is highly expressed monocytes, neutrophils, natural killer cells, on the surface of the endothelium – the thin megakaryocytes and some types of T-cell. Catalog Number layer of endothelial cells lining the interior 11256-1-AP Type Rabbit Polyclonal Applications ELISA, FC, IF, IHC, IP, WB 16 Publications Immunohistochemical of paraffin-embedded Figure 1: Immunofluorescence staining human hepatocirrhosis using PECAM1, CD31 of PECAM1 (11256-1-AP), Alexa 488 goat antibody (11265-1-AP) at a dilution of 1:50 anti-rabbit (green), and smooth muscle KD/KO Validated (40x objective). alpha-actin (red), courtesy of Nicola Smart. PECAM1: Customer Testimonial Nicola Smart, a cardiovascular researcher “As you can see [the immunostaining] is and a group leader at the University of extremely clean and specific [and] displays Oxford, has said of the PECAM1 antibody strong intercellular junction expression, (11265-1-AP) that it “worked beautifully as expected for a cell adhesion molecule.” on every occasion I’ve tried it.” Proteintech thanks Dr.
    [Show full text]
  • Regulation of Decay Accelerating Factor Primes Human Germinal Center B Cells for Phagocytosis
    ORIGINAL RESEARCH published: 05 January 2021 doi: 10.3389/fimmu.2020.599647 Regulation of Decay Accelerating Factor Primes Human Germinal Center B Cells for Phagocytosis Andy Dernstedt 1, Jana Leidig 1, Anna Holm 2, Priscilla F. Kerkman 1, Jenny Mjösberg 3, Clas Ahlm 1, Johan Henriksson 4, Magnus Hultdin 5 and Mattias N. E. Forsell 1* 1 Department of Clinical Microbiology, Section of Infection and Immunology, Umeå University, Umeå, Sweden, 2 Department of Clinical Sciences, Division of Otorhinolaryngology, Umeå University, Umeå, Sweden, 3 Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 4 Molecular Infection Medicine Sweden, Department of Molecular Biology, Umeå University, Umeå, Sweden, 5 Department of Medical Biosciences, Pathology, Umeå University, Umeå, Sweden Germinal centers (GC) are sites for extensive B cell proliferation and homeostasis is maintained by programmed cell death. The complement regulatory protein Decay Edited by: Accelerating Factor (DAF) blocks complement deposition on host cells and therefore Judith Fraussen, also phagocytosis of cells. Here, we show that B cells downregulate DAF upon BCR University of Hasselt, Belgium lo Reviewed by: engagement and that T cell-dependent stimuli preferentially led to activation of DAF B lo Paolo Casali, cells. Consistent with this, a majority of light and dark zone GC B cells were DAF and University of Texas Health Science susceptible to complement-dependent phagocytosis, as compared with DAFhi GC B Center at San Antonio, United States hi Shengli Xu, cells. We could also show that the DAF GC B cell subset had increased expression of the Bioprocessing Technology Institute plasma cell marker Blimp-1.
    [Show full text]
  • LP Review Published.Pdf
    Molecular Immunology 56 (2013) 413–422 Contents lists available at SciVerse ScienceDirect Molecular Immunology jo urnal homepage: www.elsevier.com/locate/molimm Review Toward a structure-based comprehension of the lectin pathway of complement a a b,∗ Troels R. Kjaer , Steffen Thiel , Gregers R. Andersen a Department of Biomedicine, Aarhus University, Wilhelm Meyers Allé 4, DK-8000 Aarhus, Denmark b Department of Molecular Biology and Genetics, Aarhus University, Gustav Wieds Vej 10C, DK-8000 Aarhus, Denmark a r t a b i c l e i n f o s t r a c t Article history: To initiate the lectin pathway of complement pattern recognition molecules bind to surface-linked car- Received 2 May 2013 bohydrates or acetyl groups on pathogens or damaged self-tissue. This leads to activation of the serine Accepted 14 May 2013 proteases MASP-1 and MASP-2 resulting in deposition of C4 on the activator and assembly of the C3 convertase. In addition MASP-3 and the non-catalytic MAp19 and MAp44 presumably play regulatory Keywords: functions, but the exact function of the MASP-3 protease remains to be established. Recent functional Complement system studies have significantly advanced our understanding of the molecular events occurring as activation Pattern recognition progresses from pattern recognition to convertase assembly. Furthermore, atomic structures derived MBL MASP by crystallography or solution scattering of most proteins acting in the lectin pathway and two key complexes have become available. Here we integrate the current functional and structural knowledge Protease activation C4 concerning the lectin pathway proteins and derive overall models for their glycan bound complexes.
    [Show full text]
  • Hereditary Angioedema: a Broad Review for Clinicians
    REVIEW ARTICLE Hereditary Angioedema A Broad Review for Clinicians Ugochukwu C. Nzeako, MD, MPH; Evangelo Frigas, MD; William J. Tremaine, MD ereditary angioedema (HAE) is an autosomal dominant disease that afflicts 1 in 10000 to 1 in 150000 persons; HAE has been reported in all races, and no sex predomi- nance has been found. It manifests as recurrent attacks of intense, massive, localized edema without concomitant pruritus, often resulting from one of several known trig- Hgers. However, attacks can occur in the absence of any identifiable initiating event. Historically, 2 types of HAE have been described. However, a variant, possibly X-linked, inherited angioedema has recently been described, and tentatively it has been named “type 3” HAE. Signs and symptoms are identical in all types of HAE. Skin and visceral organs may be involved by the typically massive local edema. The most commonly involved viscera are the respiratory and gastrointestinal sys- tems. Involvement of the upper airways can result in severe life-threatening symptoms, including the risk of asphyxiation, unless appropriate interventions are taken. Quantitative and functional analyses of C1 esterase inhibitor and complement components C4 and C1q should be performed when HAE is suspected. Acute exacerbations of the disease should be treated with intravenous purified C1 esterase inhibitor concentrate, where available. Intravenous administration of fresh frozen plasma is also useful in acute HAE; however, it occasionally exacerbates symptoms. Corti- costeroids, antihistamines, and epinephrine can be useful adjuncts but typically are not effica- cious in aborting acute attacks. Prophylactic management involves long-term use of attenuated androgens or antifibrinolytic agents.
    [Show full text]
  • Complement Herbert L
    Host Defense 2011 Complement Herbert L. Mathews, Ph.D. COMPLEMENT Date: 4/11/11 Reading Assignment: Janeway’s Immunobiology, 7th Edition, pp. 54-55, 61-82, 406- 409, 514-515. Figures: (Unless otherwise noted) Janeway’s Immunobiology, 7th Edition, Murphy et al., Garland Publishing. KEY CONCEPTS AND LEARNING OBJECTIVES You will be able to describe the mechanism and consequences of the activation of the complement system. To attain the goals for these lectures you will be able to: a. List the components of the complement system. b. Describe the three activation pathways for complement. c. Explain the consequences of complement activation. d. Describe the consequence of complement deficiency. Page 1 Host Defense 2011 Complement Herbert L. Mathews, Ph.D. CONTENT SUMMARY Introduction Nomenclature Activation of Complement The classical pathway The mannan-binding lectin pathway The alternative pathway Biological Consequence of Complement Activation Cell lysis and viral neutralization Opsonization Clearance of Immune Complexes Inflammation Regulation of Complement Activation Human Complement Component Deficiencies Page 2 Host Defense 2011 Complement Herbert L. Mathews, Ph.D. Introduction The complement system is a group of more than 30 plasma and membrane proteins that play a critical role in host defense. When activated, complement components interact in a highly regulated fashion to generate products that: Recruit inflammatory cells (promoting inflammation). Opsonize microbial pathogens and immune complexes (facilitating antigen clearance). Kill microbial pathogens (via a lytic mechanism known as the membrane attack complex). Generate an inflammatory response. Complement activation takes place on antigenic surfaces. However, the activation of complement generates several soluble fragments that have important biologic activity.
    [Show full text]
  • Complement Modulates the Cutaneous Microbiome and Inflammatory Milieu
    Complement modulates the cutaneous microbiome and inflammatory milieu Christel Chehouda, Stavros Rafailb, Amanda S. Tyldsleya, John T. Seykoraa, John D. Lambrisb,1, and Elizabeth A. Gricea,1 Departments of aDermatology and bPathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104 Edited by Andrea J. Tenner, University of California, Irvine, CA, and accepted by the Editorial Board August 2, 2013 (received for review April 26, 2013) The skin is colonized by a plethora of microbes that include systemic lupus erythematosus, lichen planus, xeroderma pigmento- commensals and potential pathogens, but it is currently un- sum, and recurrent cutaneous infection (15–18). known how cutaneous host immune mechanisms influence the Complement is triggered by one of three pathways (classical, composition, diversity, and quantity of the skin microbiota. alternative, or lectin), which all converge in the activation of the Here we reveal an interactive role for complement in cutaneous third complement component (C3). Following activation, the host–microbiome interactions. Inhibiting signaling of the com- release of biologically active proteins promote diverse defense plement component C5a receptor (C5aR) altered the composi- mechanisms such as microbial opsonization and phagocytosis, tion and diversity of the skin microbiota as revealed by deep direct lysis of target microbial cells through the membrane attack sequencing of the bacterial 16S rRNA gene. In parallel, we dem- complex (MAC), and the generation of effector molecules that fl onstrate that C5aR inhibition results in down-regulation of mediate recruitment and activation of in ammatory cells (13). genes encoding cutaneous antimicrobial peptides, pattern recog- This latter function, mediated by the complement C3a and C5a nition receptors, and proinflammatory mediators.
    [Show full text]
  • Development and Validation of a Protein-Based Risk Score for Cardiovascular Outcomes Among Patients with Stable Coronary Heart Disease
    Supplementary Online Content Ganz P, Heidecker B, Hveem K, et al. Development and validation of a protein-based risk score for cardiovascular outcomes among patients with stable coronary heart disease. JAMA. doi: 10.1001/jama.2016.5951 eTable 1. List of 1130 Proteins Measured by Somalogic’s Modified Aptamer-Based Proteomic Assay eTable 2. Coefficients for Weibull Recalibration Model Applied to 9-Protein Model eFigure 1. Median Protein Levels in Derivation and Validation Cohort eTable 3. Coefficients for the Recalibration Model Applied to Refit Framingham eFigure 2. Calibration Plots for the Refit Framingham Model eTable 4. List of 200 Proteins Associated With the Risk of MI, Stroke, Heart Failure, and Death eFigure 3. Hazard Ratios of Lasso Selected Proteins for Primary End Point of MI, Stroke, Heart Failure, and Death eFigure 4. 9-Protein Prognostic Model Hazard Ratios Adjusted for Framingham Variables eFigure 5. 9-Protein Risk Scores by Event Type This supplementary material has been provided by the authors to give readers additional information about their work. Downloaded From: https://jamanetwork.com/ on 10/02/2021 Supplemental Material Table of Contents 1 Study Design and Data Processing ......................................................................................................... 3 2 Table of 1130 Proteins Measured .......................................................................................................... 4 3 Variable Selection and Statistical Modeling ........................................................................................
    [Show full text]